Agios has a live FDA catalyst ahead: mitapivat received Priority Review in sickle cell disease with a Nov. 1, 2026 PDUFA date, while Q2 showed $41M of U.S. mitapivat product revenue and 442 cumulative AQVESME prescriptions [#28, #41]. Analysts also framed the SCD opportunity as material, with Leerink modeling $554M peak U.S. sales and a 60% probability of success after Priority Review [#49]. The stock’s washout now has a forward approval window and fresh commercial traction to support a tactical reversal.

CAPR has collapsed after FDA briefing concerns and a 3-9 AdCom vote, but the forward setup is still the August 22 PDUFA for Deramiocel rather than the already-fired panel reaction [#28, #32, #38]. The bull case is that FDA could still approve or conditionally approve on a narrower DMD label, with supporters pointing to PUL/LVEF arguments, SAP process defenses, and published 54% slowing of upper-limb decline in The Lancet [#2, #17, #20, #21, #24]. That makes the trade a high-risk regulatory mean reversion: the stock has repriced for failure, while the final agency decision remains open.

KTOS has a forward catalyst in the expected official announcement of a billion-dollar-plus hypersonic contract, alongside potential Taiwan Mighty Hornet demand [#2]. The setup is reinforced by IR-confirmed commentary around a potential $10 billion future annual revenue opportunity and Jefferies reiterating Buy with an $80 target on valuation de-rating, margin expansion, and a positive fundamental outlook [#1, #5].

NuScale’s tactical bounce has a concrete why-now hook: the Q2 call is set for Aug. 5, with investors watching for PPA progress tied to ENTRA1 and TVA [#2]. The setup is strengthened by estimates that the $1B ATM is likely complete or nearly complete, shifting the debate from dilution pressure toward ATM clarity, commercial de-risking, and binding contract value [#8, #10]. July nuclear policy support and AI data-center power demand add sector-level pressure for the advanced nuclear trade to re-rate [#7].

Western Union has a forward M&A hook: the company and Intermex issued an update on the pending acquisition approval process [#14, #17]. The reversal has a narrative beyond a cheap stock because bulls argue revenue fell from about $5B to $4B while the equity fell far more than fundamentals justify [#8, #45].